Respira Therapeutics, Inc.

Industry

  • Pharmaceuticals
    • Drug Delivery
      • Pulmonary
  • Biotechnology
  • Medical Devices
See more in Biomedtracker

Latest on Respira Therapeutics, Inc.

Scrip

Deal Watch: Gilead’s Immunology Collaboration With Verily Continues Pivot Away From Virology

 
• By Joseph Haas, Ian Haydock, and Lucie Ellis-Taitt

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy recent transactions. Deal Watch is supported by deal in

Scrip

Deal Watch: United Therapeutics Looks To Extend PAH Dominance With Respira's Combo Product

 
• By Joseph Haas, Ian Haydock, Lubna Ahmed, and Jung Won Shin

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy recent transactions that occurred from March 30-April 1

Scrip

Venture Funding Deals: Cell Medica Raises $73.2m, Tango Dances In With $55m

 
• By Deanna Kamienski, Beth Allan, and Maureen Riordan

Derived from Strategic Transactions , Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging bioph

In Vivo

Deals Shaping The Medical Industry, May 2017

 
• By Beth Allan, Deanna Kamienski, Maureen Riordan, Amanda Micklus, and Steven Muntner

IN VITRO DIAGNOSTICS Financings Quotient Ltd. Quotient Ltd. netted $45.4mm through a public sale of 8mm ordinary shares (including the overallotment) at $6. Funds will support ongoing scale-up and